Source - RNS
RNS Number : 8846I
PureTech Health PLC
06 September 2016
 

6 September 2016

PureTech Health plc

 

PureTech's Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia

 

PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary biotech company developing 21st century medicines in and at the interface of the immune, central nervous and gastro-intestinal systems, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued a third U.S. Patent to Vedanta Biosciences that broadly covers methods of treating a variety of diseases including infectious and allergic diseases with mixtures of Clostridium live bacterial strains. U.S. Patent No. 9,433,652 is the latest addition to Vedanta Biosciences' patent portfolio after the issuances of U.S. 9,415,079 on 16 August, U.S. 9,421,230 on 23 August and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.

 

Daphne Zohar, Co-Founder and Chief Executive Officer at PureTech, said: "Together, we believe that these three patents solidify our IP leadership position in the immune-microbiome space."

 

The full text of the announcement from Vedanta Biosciences is as follows:

 

Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia

 

CAMBRIDGE, Massachusetts, September 6, 2016 - Vedanta Biosciences, pioneering the development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,652. The patent broadly covers methods of treating a variety of diseases including infectious and allergic diseases with mixtures of Clostridium live bacterial strains and further expands Vedanta Biosciences' patent portfolio after the issuances of U.S. 9,415,079 and U.S. 9,421,230 in August and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.

 

The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta Biosciences. Dr. Honda's work shows that compositions of bacterial strains belonging to Clostridium clusters IV and/or XIVa may potentially be used to treat a range of diseases including infectious, allergic and autoimmune diseases.

 

"This third U.S. issuance further reinforces our patent portfolio around products based on bacterial consortia, and it also provides important protection for several programs in our pipeline," said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences.

 

About Vedanta Biosciences

Vedanta Biosciences is pioneering development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, with clinical trials in certain indications expected to begin in the first half of 2017. Founded by PureTech Health (PureTech Health plc, PRTC.L) and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live commensal microbes. Leveraging its proprietary technology platform and the expertise of its team of scientific cofounders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterised how the immune system recognises and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses - including induction of regulatory T cells and Th17 cells, among others - as well as the characterisation of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomised, controlled trials in infectious disease and inflammatory bowel disease.

 

Vedanta Biosciences' scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University).

 

PureTech Health plc (PRTC.L) owns 75.4% of the company on a diluted basis as of 6 June 2016. This calculation includes issued and outstanding shares as well as options to purchase shares and written commitments to issue shares or options, but excludes unallocated shares authorised to be issued pursuant to equity incentive plans.

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech company focussed on areas of growing scientific and technical insights that it believes are at an important inflection point, including the immune, central nervous and gastro-intestinal systems, and the interactions and signalling between them. PureTech has approximately 20 clinical studies across its pipeline targeting multi-billion dollar market opportunities, including five human proof-of-concept studies and multiple pivotal or registration study readouts expected in the next two years. While inevitably some technologies will not advance to commercialisation, PureTech's approach mitigates risk as most of the cash resides on a PureTech parent company level, allowing PureTech to build value and divert cash to its most successful programmes as milestones are achieved. PureTech has over 220 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit www.puretechhealth.com and connect with us on Twitter.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Enquiries

 

PureTech

Allison Mead, Director, Communications and Investor Relations

+1 617 651 3156

 

FTI Consulting (Communications adviser to PureTech)

Ben Atwell

Matthew Cole

 

+44 (0) 20 3727 1000

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFFLAFIFIIR

Related Charts

Puretech Health (PRTC)

-0.12p (-0.09%)
delayed 17:15PM